Results 11 to 20 of about 2,896 (157)

Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control [PDF]

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.
Andrea Visentin   +92 more
wiley   +2 more sources

Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study [PDF]

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Background Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...
John M. Burke   +10 more
wiley   +2 more sources

Zanubrutinib Combined With Venetoclax for the Treatment of Central Nervous System‐Involved Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case Report [PDF]

open access: yesCancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Background Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly
Wei Xie   +4 more
wiley   +2 more sources

Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy [PDF]

open access: yesHematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. The introduction of targeted therapies has expanded first‐line treatment options, which differ across multiple relevant dimensions, making therapeutic decisions increasingly challenging.
Paolo Sportoletti   +10 more
wiley   +2 more sources

Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score‐Matched Real‐World Analysis [PDF]

open access: yesCancer Medicine
Background Bruton tyrosine kinase inhibitors are central to the treatment of relapsed or refractory mantle cell lymphoma, but cardiovascular and bleeding toxicities influence treatment selection.
Anna Homeniuk   +3 more
doaj   +2 more sources

Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study [PDF]

open access: yesCurrent Oncology
Next-generation Bruton’s tyrosine kinase inhibitors (BTKis) such as acalabrutinib and zanubrutinib have improved treatment outcomes in B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström ...
Maan Awad   +7 more
doaj   +2 more sources

Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-na¨ıve patients with chronic lymphocytic leukemia: a matchingadjusted indirect comparison [PDF]

open access: yesJournal of Comparative Effectiveness Research
Aim: Fludarabine, cyclophosphamide and rituximab (FCR) is a first-line therapy for fit treatment-naive patients with chronic lymphocytic leukemia (CLL); however, its hematotoxicity and related infections necessitate more efficacious, safer treatments ...
Talha Munir   +6 more
doaj   +2 more sources

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL [PDF]

open access: yesOncology and Therapy
Introduction There is a dearth of head-to-head studies comparing covalent Bruton tyrosine kinase (cBTK) inhibitors in adults with chronic lymphocytic leukemia (CLL).
Daniel A. Ermann   +12 more
doaj   +2 more sources

Bilateral Cystoid Macular Edema with Zanubrutinib Therapy: A Case Report

open access: yesCase Reports in Oncology, 2023
We present a patient with recurrent mantle cell lymphoma (MCL) who was treated with zanubrutinib, a Bruton’s tyrosine kinase inhibitor. He subsequently developed bilateral cystoid macular edema (CME) in both eyes.
Dante Pennipede   +2 more
doaj   +1 more source

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

open access: yesPharmacology Research & Perspectives, 2021
Zanubrutinib is a highly selective, potent, orally available, targeted covalent inhibitor (TCI) of Bruton's tyrosine kinase (BTK). This work investigated the in vitro drug metabolism and transport of zanubrutinib, and its potential for clinical drug–drug
Heather Zhang   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy